NCT06600802View on ClinicalTrials.gov

Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer

NARecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 8, 2024

Primary Completion Date

December 30, 2026

Study Completion Date

December 31, 2028

Conditions
Castration-resistant Metastatic Prostate CancerTreated by 177Lutetium-PSMA-617 (Lu-PSMA)
Interventions
BIOLOGICAL

Blood samples

A total of 3 blood samples (2 tubes of 9mL each) are added. The first sample will be taken at the inclusion visit, the 2nd at the end of the 2nd treatment cycle and the last at the end of Lu-PSMA treatment.

Trial Locations (5)

38700

NOT_YET_RECRUITING

CHU de Grenoble, La Tronche

42100

NOT_YET_RECRUITING

Hôpital privé de la Loire, Saint-Etienne

63011

RECRUITING

Centre Jean PERRIN, Clermont-Ferrand

67091

NOT_YET_RECRUITING

Institut de Cancérologie Strasbourg Europe, Strasbourg

69310

NOT_YET_RECRUITING

Hospices Civiles de Lyon, Pierre-Bénite

All Listed Sponsors
collaborator

Groupement Inter-Régional de Recherche Clinique et d'Innovation (GIRCI) Auvergne Rhône-Alpes

UNKNOWN

lead

Centre Jean Perrin

OTHER